Ginkgo Bioworks surges 21%; up 120% over last month
Ginkgo Bioworks shares surged 21%, bringing its gains over the past month to 120%.
The entry-point closing price of $12.41 on October 6, 2026, was situated just below the 20-day resistance level of $13.41, and according to the REPORTING comments, the current stock price of $14.98 had broken upward through the resistance level. Despite the recent 7-day volatility of +43.9% and an RSI of 82.1 (overbought), strong upward momentum prevailed, prompting consideration for purchase in the breakout zone above the resistance level.
If I were to execute this trade, I would take profit at the current price of $13.41 if it holds the resistance level or rises, and cut losses if the price falls below the support level of $6.52.
RSI(14) 82.1 → Overbought, Moving averages not in proper alignment → Trend unstable, Volume 1.02x compared to 20-day average → Volume slightly increased, 7-day volatility +43.9% → Strong upward trend
The projected return of 3.5% was partially accurate in reflecting upward momentum and positive news catalysts, but the actual result missed the mark significantly at -17.2%. Attempting an entry despite the RSI being at 82.1 in an overbought state, and re-entering after breaking through the resistance level, were the causes of underestimating the risk. In addition, although the stop-loss was set at $6.52, the failure to react quickly enough during the sharp decline amplified the loss.
For the next trade, refrain from entering during RSI overbought zones and take positions only when a bullish moving average alignment is confirmed. Set the stop-loss tighter to account for current volatility, and use sudden volume spikes as an additional filter. Furthermore, rather than making purchasing decisions based solely on positive news catalysts, prioritize technical signals and risk management rules.